The Life Sciences Report
Notable Quotes
"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >
"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie More >
"NEO has been able to continue to grow the topline nicely and maintain margins of more than 45%." (5/30/13) NeoGenomics Laboratories - The Life Science Report with Kevin DeGeeter More >
"OPK's 4Kscore is approved in Europe and should be approved in the U.S. sometime in 2013." (5/30/13) OPKO Health Inc. - The Life Science Report with Kevin DeGeeter More >
"CTH is very early in the game with a very good and relatively derisked idea." (5/30/13) Cynapsus Therapeutics Inc. - The Life Science Report with Ori Hershkovitz More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk High: | ||
Experts Commenting on This Company
|
Oculus Innovative Sciences Inc.TICKER: OCLS:NASDAQOculus Innovative Sciences Inc. is a commercial healthcare company that develops, manufactures and markets a family of products based upon the Microcyn technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, to increase blood flow to the wound site, reduce both inflammation and pain while assisting in faster wound closure, and the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. |
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
Robert Wasserman, Dawson James Securities (4/10/13) "Oculus Innovative Sciences Inc. reported financial results for Q3/13 (ending September) earlier this year, including total revenues of $3.5M, up 29% year over year. . .we are forecasting that the company will reach breakeven operations next fiscal year (begun on April 1) and achieve positive operating cashflow. . .with an improved balance sheet, growing revenue momentum leading to estimated breakeven operations, and a solid, multinational product pipeline, we believe there is still appreciation left for Oculus shareholders at these levels and thus we are maintaining our Buy rating."
Robert Wasserman, Dawson James Securities (4/10/13) "Oculus Innovative Sciences Inc. reported financial results for Q3/13 (ending September) earlier this year, including total revenues of $3.5M, up 29% year over year. . .we are forecasting that the company will reach breakeven operations next fiscal year (begun on April 1) and achieve positive operating cashflow. . .with an improved balance sheet, growing revenue momentum leading to estimated breakeven operations, and a solid, multinational product pipeline, we believe there is still appreciation left for Oculus shareholders at these levels and thus we are maintaining our Buy rating."
Marco Rodriguez, Stonegate Securities (3/1/13) "With a tested technology, large target markets, and expecting positive adjusted EBITDA in FY/13, Oculus Innovative Sciences Inc. appears well positioned for growth. . .total revenues increased $0.760M (or 26.9%) to $3.5M, compared to $2.8M in the prior year period, with increases in the United States and Mexico. . .gross profit reported was $2.5M and gross margin was 70%, compared to a gross profit of $1.9M or 66%, for the same period in the prior year. . .we note that there is more value potential in the acute wound care opportunity."
The Life Sciences Report Interview with Josh Levine (1/3/13) "Oculus Innovative Sciences Inc. company has developed an outstanding medical product called Microcyn. It is an anti-infective agent that comes in a solution and hydrogel. It's pH neutral and is similar to the hypochlorous acid that is produced by neutrophils (a type of white blood cell), which respond to infection, kill bacteria and promote healing. White blood cells release this natural oxidant to fight invading pathogens. Microcyn works according to a carefully controlled chemistry that appears to mimic the body's natural mechanisms. . .Currently, Microcyn is generally applied to wounds and promotes healing. As the company has moved along it has found hundreds of different uses, including dermatological, oral and surgical uses among a range of vertical markets. Microcyn is very effective because of its anti-infective properties—it kills virtually all bacteria, viruses and fungi—and it has been shown to reduce inflammation, promote oxygen flow and contribute to more rapid healing. . .and Microcyn shows no development of bacterial resistance, which is a huge problem in the antibiotic world." More >
Ross Silver, Vista Partners (1/3/13) "Oculus Innovative Sciences Inc. provided a H2/12 business update in which it stated revenue was $8.6M in the six months ended September 30, 2012, compared to $6.6M in the same period last year with product revenue growing at 32% over the same period last year. . .Oculus management believes the combination of the growing revenue, especially in the United States, and reduced operating expenses in Mexico should result in consistent EBITDAS profitability sometime in fiscal year 2014, excluding expenses directly related to clinical drug trials."
